

RECOMMENDED ANTISEPTICS FOR KILLING BACTERIAL GROWTH IN NEONATAL BLUE BULB SYRINGES: ADDRESSING A CLINICAL ISSUE

Linda A Hanson, MBA, AB, Honors BSN Student and Pamela V. O'Neal, PhD, RN



RESULTS

Disinfection of E. coli V050-A1 in Mueller-Hinton broth, 22C, with different

antiseptics at multiples of the Minimum Inhibitory Concentration (MIC)



INTRODUCTION

Blue Bulb Syringes (BBSs)

- Used to remove oral and nasal secretions from newborns
- Provided to parents at hospital discharge
- Can be purchased by parents for home use during times of respiratory illness
- Multi-use device
- Current recommendation for cleaning: rinsing in warm, soapy water
- Previous research identified bacterial growth in a BBS¹
- No research studies have identified the efficacy of cleaning methods for killing bacteria growing in secretions inside the
- Three inexpensive, widely-available antiseptics are effective in killing bacterial growth within a BBS



METHODS

Why Escherichia coli?

- Most common bacteria (approximately 10%) found in BBS used in vaginal deliveries¹
- Leading cause of neonatal sepsis in newborns^{2,3}
- Leading cause of Early Onset Neonatal Bacterial Meningitis (EONBM)⁴

Experimental study

Intervention

Negative control experiment showed that intervention is necessary to achieve bactericidal state

Application of a specific concentration of selected antiseptic Experiments run in triplicate to ensure integrity of results

Null hypothesis

Intervention would have no impact on bacterial colony count

Hydrogen Peroxide: Equate® hydrogen peroxide


Criteria for selection of antiseptic included being inexpensive and widely available:

Triclosan: active ingredient in Equate® antibacterial dish detergent

Povidone-Iodine: active ingredient in Equate® antiseptic and Betadine, used in some

countries as mouthwash for VAP prevention I-Lactic Acid: active ingredient in Palmolive® antibacterial dish detergent

Chlorhexidine Gluconate: active ingredient in Peridex® mouthwash



→ Negative Control

-- Hydrogen Peroxide 5*MIC

→I-Lactic Acid 4*MIC			→ Chlorhexidine Gluconate 5*MIC		
Antiseptic	Antiseptic Cost with 8 oz. sterile water	FDA Approved	Pros	Cons	Application of Use
Triclosan	\$0.58	Currently approved, but banned beginning in 2019	Commonly found in household products	Ineffective in killing E. coli in under 30 minutes	Not recommended; research supports FDA ban
Hydrogen Peroxide	\$0.21	Yes	Inexpensive	4 minutes to kill 99% of E. coli	Home use, since it require 10 minute soak
Povidone-iodine	\$0.26	Not for mucosal contact	Killed 99% of E. coli in 27 seconds	Not currently FDA approved for mucosal contact	Countries which permit mucosal contact
-Lactic acid	\$3.66	Yes	Killed 99% pf E. coli in 26 seconds	Most expensive option	Home use, followed by rinse with clean water and drip dry
Chlorhexidine gluconate	\$3.15	Yes	Killed 99% of E.coli in 25	Surgical scrub strength (4%)	Hospital or home use, must

seconds

→ Triclosan 5*MIC

Povidone-Iodine 4*MIC

causes

rats

ARDs/death in

be mouthwash

strength (0.12%)

PRACTICE IMPLICATIONS

- Blue Bulb Syringes have the potential to cause disease in a newborn or young child if reused
- Three antiseptics identified which are more effective than the current recommendation at killing bacterial growth in a BBS
- Identified antiseptics are inexpensive and widely available and can be used in underdeveloped areas of the world
- Effective killing of bacteria in a has potential to break the chain of infection at the mode of transmission
- has a rapid kill rate, and is widely available

I-lactic acid is FDA approved,

I-Lactic Triclosan acid Chlorhexidine gluconate Povidoneiodine Hydrogen Peroxide

SELECTED REFERENCES

REFERENCES

- 1. O'Neal, P. V., Adams, E. D., Hanson, L. A., Damron, N. E., Alexander, M. B., Zhang, X., Leahy, J. G. (2017). Microbial profile and characterization of blue bulb manual suction devices used to promote airway clearance in newborns in intrapartum and postpartum units. American Journal of Infection Control. In press.
- 2. Bizzarro, M. J., Shabanova, V., Baltimore, R. S., Dembry, L., Ehrenkranz, R. A., & Gallagher, P. G. (2015). Neonatal sepsis 2004-2013: the rise and fall of coagulase-negative staphylococci. Journal Of Pediatrics, 166(5), 1193-1199. doi:10.1016/j.jpeds.2015.02.009
- 3. Kerur, B. J., Bhat, B. V., Harish, B. N., Habeebullah, S., & Kumar, C. U. (2006). Maternal Genital Bacteria and Surface Colonization in Early Neonatal Sepsis, Indian Journal of Pediatrics, 73(1), 29-
- 4. May, M., Daley, A., Donath, S., & Isaacs, D. (2005). Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. Archives Of Disease In Childhood -- Fetal & Neonatal Edition, 90(4), F324-7.

ACKNOWLEDGEMENTS

Sigma Theta Tau International, Beta Phi Chapter, UAH Research and Creative Experience for Undergraduates, UAH Laboratory assistants: Tanuj Alapati, Lana Harwell, Alex Moore The CLEAR Project Team

Marsha Adams, PhD, RN, CNE, ANEF, FAAN, Dean, College of Nursing